Chandigarh Herald

Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs

 Breaking News
  • No posts were found

Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs

August 28
22:28 2020
Spinal Muscular Atrophy Pipeline Assessment, Key Companies And Emerging Drugs

DelveInsight Business Research LLP
“Spinal Muscular Atrophy Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Spinal Muscular Atrophy market.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial assessment and clinical assessment of the Spinal Muscular Atrophy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Muscular Atrophy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

 

 

 

Spinal Muscular Atrophy pipeline possess multiple potential drugs in late and mid stage developments to be launched in the near future. Some of the key players developing therapies for the treatment of patients with Spinal Muscular Atrophy includes:
Novartis
PTC Therapeutics
Cytokinetics
Astellas
Catalyst Pharmaceuticals
Biogen
Novartis
Hoffmann-La Roche
And many others.

 

Drugs Covered
Reldesemtiv (CK-2127107)
Amifampridine Phosphate (Firdapse)
BVS 857
SRK-015
Branaplam (LMI070)
And few others.

 

Spinal Muscular Atrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Spinal Muscular Atrophy treatment.

  • Spinal Muscular Atrophy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

 

Scope of the report

  • The Spinal Muscular Atrophy Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Spinal Muscular Atrophy across the complete product development cycle, including all clinical and nonclinical stages.

  • It comprises of detailed profiles of Spinal Muscular Atrophy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details

  • Detailed Spinal Muscular Atrophy research and development progress and trial details, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Spinal Muscular Atrophy.

 

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Spinal Muscular Atrophy.    

In the coming years, the Spinal Muscular Atrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

The companies and academics that are working to assess challenges and seek opportunities that could influence Spinal Muscular Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Spinal Muscular Atrophy treatment market. Several potential therapies for Spinal Muscular Atrophy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Spinal Muscular Atrophy market size in the coming years.  

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Spinal Muscular Atrophy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

 

Table of Content

1. Report Introduction

2. Spinal Muscular Atrophy 

3. Spinal Muscular Atrophy Current Treatment Patterns

4. Spinal Muscular Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Spinal Muscular Atrophy Late Stage Products (Phase-III)

7. Spinal Muscular Atrophy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Spinal Muscular Atrophy Discontinued Products

13. Spinal Muscular Atrophy Product Profiles

14. Spinal Muscular Atrophy Key Companies

15. Spinal Muscular Atrophy Key Products

16. Dormant and Discontinued Products

17. Spinal Muscular Atrophy Unmet Needs

18. Spinal Muscular Atrophy Future Perspectives

19. Spinal Muscular Atrophy Analyst Review  

20. Appendix

21. Report Methodology

 

Related Reports

Spinal Muscular Atrophy (SMA) Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s “Spinal Muscular Atrophy (SMA) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Spinal Muscular Atrophy (SMA), historical and forecasted epidemiology as well as the Spinal Muscular Atrophy (SMA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Spinal Muscular Atrophy (SMA) Epidemiology Forecast to 2030

DelveInsight’s Spinal Muscular Atrophy (SMA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Spinal Muscular Atrophy (SMA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles